Tyrosine Kinase Inhibitor
Nintedanib for Interstitial Lung Disease
Recruiting2 awardsPhase 4
Los Angeles, California
This trial tests nintedanib, a drug that slows lung damage, in patients with myositis-associated interstitial lung disease. It works by blocking proteins that cause lung inflammation and scarring. Nintedanib has been approved for treating certain lung diseases and has shown positive results in various conditions.
Monoclonal Antibodies
Daxdilimab for Inflammatory Myositis
Recruiting0 awardsPhase 2
Anaheim, California
This trial is testing daxdilimab, a new medicine, to see if it can help patients with specific muscle and skin diseases by reducing inflammation and symptoms. The study focuses on patients with dermatomyositis or anti-synthetase inflammatory myositis.
Monoclonal Antibodies
Nipocalimab for Myositis
Recruiting0 awardsPhase 2
Beverly Hills, California
This trial is testing Nipocalimab, a medicine that blocks harmful antibodies, in patients with muscle weakness and other issues due to idiopathic inflammatory myopathies (IIM). The goal is to see if it can improve their condition by lowering harmful antibody levels.
Anti-metabolites
ADI-001 for Lupus Nephritis
Recruiting1 awardPhase 1
Manhasset, New York
This trial is testing a new treatment for lupus nephritis in multiple centers. It will involve different stages like screening, treatment, and follow-up to find the appropriate dose and assess its safety and effectiveness
Popular Filters
Trials for Systemic Lupus Erythematosus Patients
TYK2/JAK1 Inhibitor
Brepocitinib for Dermatomyositis
Recruiting1 awardPhase 3
Orlando, Florida
This trial tests brepocitinib, a drug that blocks inflammation-causing proteins, in adults with dermatomyositis. The goal is to see if it improves symptoms like muscle weakness and skin rashes by reducing inflammation. Another similar drug has shown positive results in treating difficult cases of dermatomyositis.
CAR T-cell Therapy
CAR T Therapy for Dermatomyositis
Recruiting1 awardPhase 1
Stanford, California
This trial tests a new therapy in adults with dermatomyositis. The therapy modifies their white blood cells to target and destroy harmful B cells, aiming to reset their immune system and reduce disease symptoms. This new treatment shows promising results in similar conditions.
Trials for SLE Patients
TYK2/JAK1 Inhibitor
Brepocitinib for Dermatomyositis
Recruiting1 awardPhase 3
Orlando, Florida
This trial tests brepocitinib, a drug that blocks inflammation-causing proteins, in adults with dermatomyositis. The goal is to see if it improves symptoms like muscle weakness and skin rashes by reducing inflammation. Another similar drug has shown positive results in treating difficult cases of dermatomyositis.
CAR T-cell Therapy
CAR T Therapy for Dermatomyositis
Recruiting1 awardPhase 1
Stanford, California
This trial tests a new therapy in adults with dermatomyositis. The therapy modifies their white blood cells to target and destroy harmful B cells, aiming to reset their immune system and reduce disease symptoms. This new treatment shows promising results in similar conditions.
Phase 3 Trials
ABC008 for Inclusion Body Myositis
Recruiting0 awardsPhase 2 & 3
Phoenix, Arizona
This trial is testing a new drug called ABC008 to help people with Inclusion Body Myositis, a muscle disease with few treatment options. The drug may work by affecting certain immune cells. Researchers will check if it improves muscle strength and quality of life.
TYK2/JAK1 Inhibitor
Brepocitinib for Dermatomyositis
Recruiting1 awardPhase 3
Orlando, Florida
This trial tests brepocitinib, a drug that blocks inflammation-causing proteins, in adults with dermatomyositis. The goal is to see if it improves symptoms like muscle weakness and skin rashes by reducing inflammation. Another similar drug has shown positive results in treating difficult cases of dermatomyositis.
Sirolimus for Inclusion Body Myositis
Recruiting1 awardPhase 3
Baltimore, Maryland
This trial tests Sirolimus, a drug used in organ transplants, on patients with Inclusion Body Myositis (IBM). IBM causes muscle weakness, and current treatments are often ineffective. Sirolimus may help by calming harmful immune responses and cleaning up damaged proteins in muscle cells. Sirolimus has been used in organ transplant recipients to reduce the risk of skin cancer and manage immune system activity.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.